



CeQur Simplicity™

Convenient, discrete, 3-Day, wearable insulin Patch for injection-free dosing

Mealtime insulin is always within reach

Designed to remove the inconvenience, embarrassment, and pain of rapid insulin dosing

- Simple to use
- Discreet
- Wearable 3-day insulin patch
- For injection-free mealtime dosing



A two-button squeeze delivers 2U of rapid-acting insulin via a soft flexible cannula, enabling fast and discreet dosing in any situation.

Holds up to 200 units, compatible with both U-100 rapid-acting Humalog® and Novalog®.

Removing known barriers to insulin dosing may help patients achieve glycemic targets¹

88% of patients said CeQur Simplicity helps them do a better job of following their insulin regimen²

1. Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B. 2019. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. *Diabetes Technology and Therapeutics* 21 (5):1-13.
2. Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. 2016. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at the American Diabetes Association's 76th Scientific Sessions. Abstract 995-P. New Orleans, LA, USA

Abundant research shows CeQur Simplicity™ can improve glycemic control

Clinical support:

- Studied in more than 450 patients^{1,2,3,4}
- Publications: 4 major papers and 4 original abstracts

Results from Clinical Outcomes Study (n=278):


- Getting patients to goal:
 - › A total of **63% of patch users achieved A1C ≤7.0** at week 24¹
 - › A total of **85% of patch users achieved A1C ≤8.0** at week 24
- This number was sustained at the end of the study at week 44⁵

Safety:

- No differences were observed for reported hypoglycemia between groups¹

Clinical Outcome Study Findings¹

Mean A1C was reduced to target goal by Week 24



Consistent A1C <7% supports HEDIS Comprehensive Diabetes Care measure



n=278

1. Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B. 2019. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. *Diabetes Technology and Therapeutics* 21 (5):1-13.
2. Bohannon N, Bergenstal R, Cuddihy R, et al. Comparison of a novel insulin bolus-patch with pen/syringe injection to deliver mealtime insulin for efficacy, preference, and quality of life in adults with diabetes: a randomized, crossover, multicenter study. *Diabetes Technol Ther.* 2011;13(10):1031-1037.
3. Peyrot M, Dreon D, Zraick V, Cross B, Tan MH. Patient perceptions and preferences for a mealtime insulin delivery patch. *Diabetes Ther.* 2018;9(1): 297-307.
4. Zraick V, Dreon D, Naik R, Shearer D, Crawford S, Bradford J, Levy B. 2016. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at the American Diabetes Association's 76th Scientific Sessions. Abstract 995-P. New Orleans, LA, USA
5. Barry R, Johns D, Rees B. 2019. Transitioning T2DM Patients to Basal-Bolus Insulin Leads to Sustainable A1C Improvement, *Diabetes* 2019 Jun; 68(Supplement 1)

CeQur Simplicity™ gives patients more time in range

After 24 weeks, patients using CeQur Simplicity increased their time in target range by 50%¹

The International consensus on time-in-range defines clinical target for TIR $\geq 70\%$, which is evidenced to be equivalent to an A1C of $\leq 7\%$.²



1. Johnson ML, Dreon DM, Levy BL, et al. Comparing Patch versus Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles. Paper presented at: 54th Annual Meeting of the European Association for the Study of Diabetes; Oct 1-5, 2018, Berlin, Germany
2. Battelino T, Danne T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. 2019. <https://doi.org/10.2337/dci19-008>

CeQur Simplicity™ delivers high patient and provider satisfaction^{1,2,3,4}


Patients using CeQur Simplicity reported:

- Higher overall satisfaction
- Satisfaction with ease of use

HCPs claimed that they:

- Preferred the patch to pen to advance T2DM patients from basal to basal/bolus insulin
- Were satisfied with the patch
- Found training the patients to use the patch easy

Patient reported outcomes compared to pen¹



1. Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B. 2019. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. *Diabetes Technology and Therapeutics* 21 (5):1-13.
2. Bohannon N, Bergenstal R, Cuddihy R, et al. Comparison of a novel insulin bolus-patch with pen/syringe injection to deliver mealtime insulin for efficacy, preference, and quality of life in adults with diabetes: a randomized, crossover, multicenter study. *Diabetes Technol Ther.* 2011;13(10):1031-1037.
3. Peyrot M, Dreon D, Zraick V, Cross B, Tan MH. Patient perceptions and preferences for a mealtime insulin delivery patch. *Diabetes Ther.* 2018;9(1): 297-307.
4. Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. 2016. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at the American Diabetes Association's 76th Scientific Sessions. Abstract 995-P. New Orleans, LA, USA